GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Rhythm Biosciences Ltd (ASX:RHY) » Definitions » Liabilities-to-Assets

Rhythm Biosciences (ASX:RHY) Liabilities-to-Assets : 0.36 (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Rhythm Biosciences Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Rhythm Biosciences's Total Liabilities for the quarter that ended in Dec. 2023 was A$0.70 Mil. Rhythm Biosciences's Total Assets for the quarter that ended in Dec. 2023 was A$1.94 Mil. Therefore, Rhythm Biosciences's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2023 was 0.36.


Rhythm Biosciences Liabilities-to-Assets Historical Data

The historical data trend for Rhythm Biosciences's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rhythm Biosciences Liabilities-to-Assets Chart

Rhythm Biosciences Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Liabilities-to-Assets
Get a 7-Day Free Trial 0.06 0.30 0.44 0.13 0.24

Rhythm Biosciences Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Liabilities-to-Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.17 0.13 0.12 0.24 0.36

Competitive Comparison of Rhythm Biosciences's Liabilities-to-Assets

For the Diagnostics & Research subindustry, Rhythm Biosciences's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rhythm Biosciences's Liabilities-to-Assets Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Rhythm Biosciences's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Rhythm Biosciences's Liabilities-to-Assets falls into.



Rhythm Biosciences Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Rhythm Biosciences's Liabilities-to-Assets Ratio for the fiscal year that ended in Jun. 2023 is calculated as:

Liabilities-to-Assets (A: Jun. 2023 )=Total Liabilities/Total Assets
=1.821/7.695
=0.24

Rhythm Biosciences's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2023 is calculated as

Liabilities-to-Assets (Q: Dec. 2023 )=Total Liabilities/Total Assets
=0.701/1.944
=0.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Rhythm Biosciences  (ASX:RHY) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.


Rhythm Biosciences Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of Rhythm Biosciences's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Rhythm Biosciences (ASX:RHY) Business Description

Traded in Other Exchanges
Address
30 Flemington Road, Bio21 Institute, Parkville, Melbourne, VIC, AUS, 3010
Rhythm Biosciences Ltd is a medical diagnostics technology company. It is engaged in developing and commercializing Australian medical diagnostics technology for sale to national and international markets. Its product includes ColoSTAT a proposed diagnostic blood test for screening for colorectal cancer. Geographically, the company operates only in Australia.

Rhythm Biosciences (ASX:RHY) Headlines

No Headlines